Compare ACET & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACET | ZTEK |
|---|---|---|
| Founded | 1947 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.6M | 68.8M |
| IPO Year | 2017 | 2022 |
| Metric | ACET | ZTEK |
|---|---|---|
| Price | $7.00 | $0.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $56.00 | N/A |
| AVG Volume (30 Days) | 111.8K | ★ 123.6K |
| Earning Date | 03-12-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.54 |
| 52 Week High | $9.05 | $1.84 |
| Indicator | ACET | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 42.10 |
| Support Level | $6.54 | $0.55 |
| Resistance Level | $8.34 | $0.67 |
| Average True Range (ATR) | 0.44 | 0.05 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 17.94 | 53.85 |
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.